Two forms of recombinant growth hormone that accelerate the healing of skin graft donor sites in severely burned children were evaluated.
Summary Background Data
Growth hormone has been shown to reduce wound healing times in burned pediatric patients. Through genetic engineering, several different forms have been synthesized; however, not all are marketed currently. Two forms of growth hormone were used in these studies, Protropin (Genentech, Inc., San Francisco, CA), a commercially available product that possesses a Nterminal methionine residue not found in the second form Nutropin (Genentech, Inc., San Francisco, CA), which, as yet, is not commercially available. Through the use of recombinant human growth hormone, rapid wound healing may reduce the hypermetabolic period, the risk of infection, and accelerate the healing of donor sites used for grafting onto burned areas. The two structurally different forms of growth hormone were tested for their efficacy in healing donor sites in severely burned children.
Methods
Forty-six children, with a >40% total body surface area and >20% total body surface area fullthickness burn were entered in a double-blind, randomized study to receive rhGH within 8 days of injury. Twenty received (0.2 mg/kg/day) Nutropin or placebo by subcutaneous or intramuscular injection beginning on the morning of the initial excision. Eighteen patients who failed the entry criteria for receiving Nutropin received Protropin therapeutically (0.2 mg/kg/day). Donor sites were harvested at 0.006 to 0.010 inches in depth and dressed with Scarlet Red impregnated fine mesh gauze (Sherwood Medical, St. Louis, MO). The initial donor site healing time, in days, was reached when the gauze could be removed without any trauma to the healed site.
Results
Donor sites in patients receiving Nutropin (n = 20) or Protropin (n = 18) healed at 6.8 ± 1.5 and 6.0 ± 1.5 (mean ± SD) days, respectively, whereas those receiving placebo (n = 26) had a first donor site healing time of 8.5 ± 2.3 days. Both groups receiving rhGH showed a significant reduction in donor site healing time compared with placebo at p < 0.01. When subgroups were compared, no difference in healing times could be shown with regards to age or time of admission after injury.
Conclusion
Our results indicate that both forms of rhGH are effective in reducing donor site healing time compared with placebo and suggest that accelerating wound healing is of clinical benefit because the patients' own skin becomes rapidly available for harvest and autografting. With this increase in the rate of wound healing, the total length of hospital stay can be reduced by more than 25%. 
RESUSCITATION AND NUTRITION
All subjects were resuscitated by a standard formula with intravenous fluids administered to maintain a urinary output of 1.0 to 1.5 mL/kg/hr. Electrolyte supplementation was given to achieve appropriate serum concentrations.9 Enteral nutritional support was given to meet calorie requirements calculated from age, body surface area, and burn size. 10-12
SURGERY
One of three surgeons excised and grafted the entire wound, excluding the face and perineum, within 48 hours of admission. Excised areas were covered with 2:1 meshed autograft, 4:1 meshed autograft with 2:1 meshed cadaveric allograft overlay, or 2:1 meshed cadaveric allograft alone if sufficient autograft donor skin was unavailable for complete 4:1 coverage. Donor sites were harvested using an electric dermatome set at 0.006 to 0.010 Foreign nationals were excluded from the double-blind Nutropin study when they were not available for follow-up after discharge.
inches and dressed with Scarlet Red (Sherwood Medical, cant differences were accepted at p < 0.05. The effect of St. Louis, MO) impregnated fine mesh gauze.
sex, age, and percent full-thickness burn on healing times On the third postoperative day, the donor site was ex-were determined by regression analysis. amined by one of two evaluators. Using sterile technique, each of the four corners of the gauze was gently RESULTS lifted using forceps and minimal tension to determine the adherence of the dressing to the underlying tissue.
Twenty-six burned children received placebo and 20 Any unattached dressing was trimmed away. This proce-received Nutropin in a randomized, double-blind study. dure was repeated daily until the Scarlet Red impreg-Eighteen children received therapeutic Protropin, 12 nated gauze was no longer adherent to the underlying within 8 days of injury and 6 between 16 and 23 days donor site wound. For the purposes ofthis study, healing after injury. The time of admission had no significant time was defined as the time, in days, for the initial donor effect on healing times in patients receiving therapeutic site to heal as indicated by atraumatic removal of the Protropin (Table 2 ). In the 18 patients given Protropin, Scarlet Red gauze (the first harvest ofa designated donor those 6 months to 2 years of age were compared to those site).
older than 2 years ( Growth hormone is released from the pituitary gland in response to stress both at night and at various times throughout the day. In patients who are recumbent for most of the time, the precise time of day for optimal administration of exogenous rhGH still has to be determined. We assumed that growth hormone given in conjunction with morning feeding would be most beneficial.
Whether rhGH specifically influences the fibroblast and other wound healing tissues to accelerate repair or whether the reduction in catabolic loss of fat and peripheral muscle increases availability of macromolecules for tissue repair is not known. It is recognized that growth hormone influences glucose metabolism. 8 '9 Total parenteral nutrition (TPN), occasionally used in trauma patients, also is a promoter of hyperglycemia. In this study, no patient received TPN. Hyperglycemia often is treated clinically with exogenous insulin, which may, if given in sufficient quantities, have an anabolic influence on protein kinetics. Studies using a hyperinsulinemic eugly- 6.0± 1.5 Data are presented as means ± SD. cemic clamp have shown an increased rate of protein synthesis, thus, theoretically increasing the availability of protein for wound repair. 6 Previous studies from this institution suggest that the combination of rhGH and insulin does not improve protein kinetics when compared with rhGH alone;'6 however, others have found that in stressed patients, rhGH and insulin combine to improve protein kinetics.20 Nine children in the Nutropin study who received exogenous insulin (range 6-151 units/day) were compared to 11 who required no insulin. Data indicate that there was no significant difference in initial donor site healing times. In addition, these results confirm the findings ofan earlier report from this institution on the effect of Nutropin alone,3 compared to placebo, on initial (first) donor site healing time (placebo: 9.1 ± 0.4 days, n = 17, compared with 8.5 ± 2.3 days, n = 26, and Nutropin: 7.4 ± 0.6 days, n = 8, compared with 6.4 ± 1.2 days, n = 1 1). The reduction in the initial donor site healing time in this study for both the placebo and Nutropin groups is a reflection of the larger numbers in each group.
In children receiving Protropin, nine patients were 6 months to 2 years old, and nine were older than 2 years. When these subgroups were compared, there was no difference in healing times, suggesting that Protropin is effective in children of all ages. Of those receiving Protropin, 6 children were given their rhGH 8 or more days after injury16-23 and 12 received Protropin less than 8 days after injury. No significant difference in healing time could be shown between these groups, suggesting that delayed admission did not influence healing times.
The dose of rhGH used in this study was based on a previous investigation in which a plasma disappearance curve was constructed after administration of0.1 mg/kg/ day or 0.2 mg/kg/day.3 This, in addition to other clinical information, indicated that 0.2 mg/kg/day would produce an effective response in donor site healing.
Our results indicate that both forms of rhGH are effective in reducing donor site healing time compared with placebo and suggest that accelerating wound healing is of clinical benefit because the patients' own skin becomes rapidly available for harvest and autografting. Further, by reducing donor site healing times, the length of hospital stay in children receiving a cutaneous fullthickness burn can be reduced by more than 25%. This study confirms the previous one in that both donor site wound healing time and hospital stay were reduced by recombinant human growth hormone. 
